Spliceosome mediated rna trans-splicing for correction of skin disorders
CA 2492469 A1 · Owner: Intronn, Inc. · Inventors: Klausegger, Alfred; Puttaraju, Madaiah; Mitchell, Lloyd G.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides methods and compositions for generating novel nucleic acid molecules through targeted spliceosomal mediated RNA trapssplicing. The compositions of the invention include pre-traps-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) and mediate a traps-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA). In particular the PTMs of the present invention can be genetically engineered to interact with a specific target pre~mRNA expressed in cells of the skin so as to result in correction of genetic defects responsible for a variety of different skin disorders …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 17, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 17, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 17, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.